



Washington State Transactions by Industry



Transactions per Quarter (Millions) 2013 to 2015*



2015* Transaction Highlights:

- Alder Biopharmaceuticals, *Second Public Offering*, \$203.6M
- Total Venture Capital Funding
 - \$28,683,845
- Total Private Equity Funding
 - \$95,629,578

*As of May 05, 2015

News highlights:

- Seattle Genetics is looking to recruit roughly 100 new workers throughout its operations accelerating its pipeline of armed antibody candidates.
- Juno Therapeutics' in-development cancer immunotherapy notched a 91% complete remission rate in a small trial on children with a form of leukemia.
- Researchers at Presage Biosciences and the Fred Hutchinson Cancer Research Center have released results from a study showing further evidence their microinjection delivery device can accurately determine which cancer drugs are effective by testing multiple drugs at once inside a tumor.

Deal highlights:

- Cardeas Pharma \$3.5M (Series B)
- Carena \$500K (Debt)
- X2 Biosystems \$350K (Venture Equity)
- Mpirica Health \$1.6M (Series A)
- Mirabilis Medica \$2.92M (Debt)
 - **April 2015 total: \$5,950,000**
 - **2015 running total: \$826,333,423**

[NIH SBIR/STTR Funding for Startups](#)

Informational Session May 28th 8 – 11AM | One-on-One Meetings May 28-29 as scheduled. SBIR & STTR experts from the National Institutes of Health will be in Seattle on May 28th and 29th to explain the secrets to success. Following the presentations, Dr. Greg Evans, National Cancer Institute (NCI), Lili Portilla, National Center for Advancing Translational Sciences (NCATS), and Todd Merchak, National Institute of Biomedical Imaging and Bioengineering (NIBIB) *will meet with WBBA members one-on-one to discuss specific grant opportunities and proposals.*

1. Register for the informational morning event at <http://tinyurl.com/WBBA-NIH>.
2. To meet w/ NCI, NCATS, and/or NIBIB Program Officers: Send a brief (1-2 page) executive summary to yesenia@washbio.org by 5PM on May 15th.

Not a WBBA Member? Contact Blythe Price at blythe@washbio.org to become one!

[Present your early stage to 1,000 attendees at Life Science Innovation Northwest, June 30-July 1!](#)

For more information and application instructions please visit <http://tinyurl.com/LSINW-Poster>.

Final applications are due May 22nd. Questions? Please contact Brady Ryan, brady@washbio.org

[Need early-stage capital? Apply to WINGS – The Washington Medical Technology Angel Network:](#)

WINGS, The Washington Medical Technology Angel Network, is the only angel group in the Pacific Northwest focused solely on medical technology. Since its formation in 2010, WINGS has evaluated hundreds of medical technology companies from around the region, investing over \$10 million in 17 companies.

Applications for the July 8, 2015 WINGS Investor Meeting are due on May 22nd and can be submitted at <https://gust.com/organizations/wings>.

For more information visit medtechwings.com, or contact Yesenia Green, yesenia@medtechwings.com.

[Start-up Weekend Bothell – Health Edition](#)

Event Sponsor: University of Washington, Bothell

Date & Time: May 15-17, starts at 6:00pm Friday, May 15

Location: UW Bothell, 18115 Campus Way Northeast, Discovery Hall, Bothell, WA

[2015 Life Science Leadership Summit](#)

Date & Time: Thursday, May 21, Registration 11:30AM | Program 12:00-5:30PM | Reception 5:30-6:30PM

Location: Washington State University, Riverpoint Campus, 205 E. Spokane Falls Blvd, Spokane, WA

[Superheroes Fighting Superbugs: Washington State on the Forefront of Antibiotic Resistance](#)

Date & Time: Wednesday, May 27, Registration 4:30PM | Program 5:00PM | Reception 6:30PM

Location: Agora Conference Center, 1551 Eastlake Ave E, Seattle, WA

[NIH SBIR/STTR Funding for Startups](#)

Date & Time: Thursday, May 28, Informational Session 8:00-11:00AM

Location: Agora Conference Center, 1551 Eastlake Ave E, Seattle, WA

Washington Life Sciences, Did You Know?

R&D Tax Credits Save Jobs... and Lives

Collaborations fuel the WA Life Sciences. R+D Tax Credits fuel collaboration.

[Micronics](#) is a Redmond medical device company that has partnered with **[Sony](#)** to help save lives. Its technologies enable point-of-care testing of disease and provide results in minutes. It was recently part of a grant along with **[Seattle Children's Research Institute](#)** to identify and track new strains of the flu.

Saving as little as \$35,000 in tax credits enabled the company to keep two people on payroll.



Washington-based Life Science Transactions 2014-2015

| Date | Company | Type | Amount |
|-------------|-----------------------------|--------------------|---------------|
| 01/07/14 | Cardiac Dimensions | Debt | \$367,000 |
| 01/08/14 | Seattle Genetics | Partnership | \$25,000,000 |
| 01/13/14 | Juno Therapeutics | Series A extension | \$25,000,000 |
| 01/13/14 | ActX | Seed equity | \$1,900,000 |
| 01/14/14 | NuvoMed | Undisclosed | \$535,000 |
| 01/21/14 | Seattle Genetics | Venture Equity | \$9,000,000 |
| 02/04/14 | Acucela | IPO (Japan) | \$162,000,000 |
| 02/12/14 | Cardiac Dimensions | debt | \$456,000 |
| 02/12/14 | Nativis | Venture Equity | \$9,160,000 |
| 02/25/14 | Cheetah Medical | Venture Equity | \$9,000,000 |
| 03/05/14 | Immunexpress | Venture Equity | \$6,000,000 |
| 03/14/14 | Kineta | Venture Equity | undisclosed |
| 03/14/14 | Nortis | Undisclosed | \$1,200,000 |
| 03/17/14 | CadenceMD | Debt | \$55,000 |
| 03/20/14 | Cardiac Dimensions | Debt | \$380,000 |
| 03/25/14 | Clarity Health | Venture Equity | \$836,000 |
| 03/25/14 | BioLife Solutions | IPO | \$15,400,000 |
| 03/25/14 | FlexMinder | Series A | \$1,200,000 |
| 03/26/14 | KinDex Pharmaceuticals | Series A | \$5,000,000 |
| 04/07/14 | Adaptive Biotechnologies | Series C&D | \$105,000,000 |
| 04/09/14 | Oricula Therapeutics | Seed equity | \$122,000 |
| 04/10/14 | Tissue Regeneration Systems | Venture Equity | \$1,500,000 |
| 04/14/14 | JeNu Biosciences | Debt | \$1,480,000 |
| 04/14/14 | Etubics | Seed equity | \$4,400,000 |
| 04/16/14 | Cardiac Dimensions | Venture Equity | \$20,000,000 |
| 04/18/14 | X2 Biosystems | Debt | \$2,510,000 |
| 04/24/14 | Juno Therapeutics | Series A extension | \$31,000,000 |
| 04/29/14 | Integrated Diagnostics | Series B and Debt | \$47,250,000 |
| 05/08/14 | Alder Biopharmaceuticals | IPO | \$80,000,000 |
| 05/13/14 | Stratos Genomics | Series B | \$10,000,000 |
| 05/14/14 | PharmaN | Venture Equity | \$1,500,000 |
| 05/15/14 | AVM Biotechnology | Series B | \$1,500,000 |
| 05/16/14 | Kineta | Equity | \$1,627,498 |
| 06/06/14 | Cheetah Medical | Venture Equity | \$5,000,000 |
| 06/06/14 | NanoString Technologies | Partnership | \$5,750,000 |
| 06/15/14 | Cardiac Insight | Partnership | \$7,000,000 |
| 07/01/14 | Pregenen | Acquired | \$20,000,000 |
| 07/11/14 | Nortis | Venture Equity | \$1,000,000 |
| 07/15/14 | Valant Medical Solutions | Venture Equity | \$11,000,000 |
| 07/18/14 | ActX | Venture Equity | \$750,000 |
| 07/21/14 | Nativis | Undisclosed | \$2,319,000 |
| 07/25/14 | Immune Design | IPO | \$60,000,000 |
| 07/29/14 | Accelerator Corporation | Venture Equity | \$51,100,000 |
| 07/29/14 | Amgen | Closing WA Offices | |
| 07/30/14 | Theraclone Sciences | Partnership | undisclosed |
| 07/30/14 | Jintronic | Debt | \$772,500 |
| 08/04/14 | Juno Therapeutics | Series B | \$134,000,000 |

Washington Life Science Report



| | | | |
|----------|----------------------------------|--------------------------------------|---------------|
| 08/07/14 | Immune Design | License | \$168,000,000 |
| 08/11/14 | Alpine BioSciences | Acquisition | \$27,000,000 |
| 08/15/14 | Carena | Debt | \$1,995,000 |
| 08/21/14 | Immunosoft | Venture Equity | \$2,300,000 |
| 09/02/14 | Clarity Health | Venture Equity | \$1,059,352 |
| 09/03/14 | NovoNordisk | Closing Inflammatory Research Center | |
| 09/10/14 | Seattle Genetics | Licensing | \$11,000,000 |
| 09/23/14 | VentiRx Pharmaceuticals | Venture Equity | \$19,300,000 |
| 09/26/14 | Array Health | Venture Equity | \$13,000,000 |
| 10/01/14 | NovoNordisk | Opening Obesity R&D | |
| 10/07/14 | Cardiac Dimensions | Venture Equity | \$8,500,000 |
| 10/08/14 | Blaze BioScience | NCI SBIR Phase II Funding | \$1,500,000 |
| 10/09/14 | Mirador Biomedical | Acquired | undisclosed |
| 10/27/14 | Limeade | Venture Equity | \$25,000,000 |
| 11/19/14 | IDRI | Contract | \$3,600,000 |
| 11/21/14 | Aortica | Series A | \$7,000,000 |
| 12/09/14 | Allen Institute for Cell Science | Paul Allen Donation | \$100,000,000 |
| 12/19/14 | Juno Therapeutics | IPO | \$264,600,000 |
| 12/30/14 | Oncogenex | Venture Equity | \$27,000,000 |
| 12/30/14 | Cerevast Therapeutics | Venture Equity | \$10,000,000 |

2014 Total **\$1,569,924,350**

| Date | Company | Type | Amount |
|----------|--------------------------|------------------------|---------------|
| 01/22/15 | Alder Biopharmaceuticals | Second public offering | \$203,600,000 |
| 01/22/15 | Adaptive Biotechnologies | Equity | \$93,750,000 |
| 01/28/15 | Vesiflo | Convertible note | \$650,000 |
| 01/30/15 | MalarVx, Inc | Equity | \$110,000 |
| 02/05/15 | Alpine Immune Sciences | Seed | \$1,300,000 |
| 02/13/15 | Stasys Medical | Series A | \$160,000 |
| 02/18/15 | StratoScientific | Venture Equity | \$550,000 |
| 02/23/15 | Dendreon | Acquisition | \$495,000,000 |
| 03/06/15 | Cerevast Therapeutics | Series C | \$1,375,000 |
| 03/09/15 | KinDex Pharmaceuticals | Series A | \$500,000 |
| 03/11/15 | Cardiac Dimensions | Venture Equity | \$15,200,000 |
| 03/19/15 | Nortis | Venture Equity | \$408,845 |
| 03/20/15 | Healthentic | Series C | \$3,750,000 |
| 03/20/15 | StratoScientific | Venture Equity | \$150,000 |
| 03/25/15 | Cadence Biomedical | Equity | \$959,578 |
| 04/10/15 | Cardeas Pharma | Series B | \$3,500,000 |
| 04/13/15 | Carena | Debt | \$500,000 |
| 04/17/15 | X2 Biosystems | Venture Equity | \$350,000 |
| 04/24/15 | Mpirica Health | Series A | \$1,600,000 |
| 05/01/15 | Mirabilis Medica | Debt | \$2,920,000 |
| 05/06/15 | Adaptive Biotechnologies | Venture Equity | \$195,000,000 |

2015 Running Total **\$1,021,333,423**

as of 05/06/15